HC Wainwright Reiterates Buy Rating for Coherus BioSciences (NASDAQ:CHRS)

Coherus BioSciences (NASDAQ:CHRS)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $12.00 price objective on the biotechnology company’s stock.

Several other research analysts have also issued reports on CHRS. UBS Group lowered Coherus BioSciences from a “buy” rating to a “neutral” rating and dropped their target price for the company from $4.00 to $1.50 in a research report on Friday, August 16th. StockNews.com lowered shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.13.

Coherus BioSciences Stock Down 1.0 %

Shares of CHRS opened at $0.72 on Thursday. The business has a fifty day moving average of $1.02 and a 200 day moving average of $1.47. The company has a market cap of $83.39 million, a PE ratio of -1.81 and a beta of 0.69. Coherus BioSciences has a 52-week low of $0.66 and a 52-week high of $3.70.

Coherus BioSciences (NASDAQ:CHRS) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The firm had revenue of $64.98 million for the quarter, compared to analysts’ expectations of $57.08 million. As a group, research analysts anticipate that Coherus BioSciences will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coherus BioSciences

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in shares of Coherus BioSciences by 694.2% in the 1st quarter. BNP Paribas Financial Markets now owns 346,157 shares of the biotechnology company’s stock worth $827,000 after acquiring an additional 302,570 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Coherus BioSciences in the 1st quarter worth approximately $94,000. AQR Capital Management LLC bought a new position in shares of Coherus BioSciences during the 2nd quarter worth approximately $1,246,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Coherus BioSciences during the first quarter valued at approximately $108,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Coherus BioSciences in the first quarter valued at approximately $349,000. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.